Effectiveness of the 6-month BPaLM regimen in a patient with rifampicin-monoresistant tuberculosis
DOI:
https://doi.org/10.61511/phraj.v3i2.2026.2224Keywords:
BPaLM, rifampicin resistance, tuberculosisAbstract
Background: Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis and remains a global health problem, including in Indonesia. Rifampicin-resistant tuberculosis (TB) (RR-TB) is a form of anti-tuberculosis drug resistance in which Mycobacterium tuberculosis only shows resistance to rifampicin, without resistance to isoniazid or other first-line drugs. The combination of Drug Resistant Tuberculosis (TB RO) treatment regimens greatly influences the effectiveness of TB RO patient treatment management. The purpose of this study was to see the effectiveness of the 6-month BPaLM regimen in a patient with rifampicin-monoresistant tuberculosis in Sabu Raijua Regional Hospital, Sabu Raijua Regency, East Nusa Tenggara. Methods: This type of research is a quantitative study with a cross-sectional approach to see the effectiveness of the 6-month BPaLM regimen in a patient with rifampicin-monoresistant tuberculosis at Sabu Raijua Regional Hospital in 1 case treated from the beginning of treatment (baseline), monthly follow-up and until the end of treatment. Findings: The study results show that the BPaLM regimen is highly effective in eradicating RR-TB in patients in areas with limited facilities, such as the 3T (terpencil, terluar, dan tertinggal/ disadvantaged, frontier, and outermost) areas. Multidisciplinary clinical, laboratory, and radiological monitoring are key to successful therapy, including early detection of side effects and ensuring adherence. Therefore, this 6-month BPaLM regimen is highly effective in assisting in the management of RR-TB treatment. Conclusion: In conclusion, the 6-month BPaLM regimen demonstrates high effectiveness in treating rifampicin-monoresistant tuberculosis (RR-TB), even in limited-resource settings such as disadvantaged, frontier, and outermost areas. Comprehensive multidisciplinary monitoring is essential to ensure treatment success and patient adherence. Novelty/Originality of this article: This study provides new evidence of the successful implementation of the 6-month BPaLM regimen for rifampicin-monoresistant tuberculosis (RR-TB) in a remote, limited-resource setting (disadvantaged, frontier, and outermost area), demonstrating its practicality and effectiveness beyond controlled or urban healthcare environments.
References
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J. C., Anderson, L. F., Baghaei, P., et al. (2018). Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. Lancet.
Conradie, F., Bagdasaryan, T. R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., et al. (2022). Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. New England Journal of Medicine, 387(9), 810–823. https://doi.org/10.1056/NEJMoa2205185
Conradie, F., Deacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., et al. (2020). Treatment of highly drug-resistant pulmonary tuberculosis. New England Journal of Medicine, 382(10), 893–902. https://doi.org/10.1056/NEJMoa1901814
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., et al. (2017). The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine, 5(4), 291–360. https://doi.org/10.1016/S2213-2600(17)30079-6
Esmail, H., Oelofse, S., Lombard, C., Badri, M., Conradie, F., van der Walt, J., et al. (2022). Early bactericidal activity of BPaLM regimen in pulmonary multidrug-resistant tuberculosis: A randomized controlled trial. Lancet Infectious Diseases, 22(10), 1522–1532. https://doi.org/10.1016/S1473-3099(22)00348-4
Esmail, A., Sabur, N. F., Okpechi, I., Dheda, K., & Chang, K. C. (2022).
Linezolid-associated toxicity in multidrug-resistant tuberculosis: A systematic review and meta-analysis. The European Respiratory Journal, 59(4), 2101919. https://doi.org/10.1183/09031936.00188114
Guglielmetti, L., Hewison, C., Avaliani, Z., Hughes, J., Jonckheere, S., Palmero, D., et al. (2022a). Compassionate use of new drugs in extensively drug-resistant tuberculosis: Bedaquiline, delamanid, and pretomanid. European Respiratory Journal, 59(4), 2101806. https://doi.org/10.1183/13993003.01806-2021
Guglielmetti, L., Jaspard, M., Le Dû, D., Lachâtre, M., Marigot-Outtandy, D., Bernard, C., Veziris, N., & Caumes, E. (2022b). Long-term outcome and safety of bedaquiline-containing regimens in multidrug-resistant tuberculosis. The European Respiratory Journal, 59(3), 2101688. https://doi.org/10.1183/13993003.01799-2016
Johnson, T. M., Rivera, C. G., Lee, G., & Zeuli, J. D. (2024a). Pharmacology of emerging drugs for the treatment of multidrug-resistant tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 37, 100470. https://doi.org/10.1016/j.jctube.2024.100470
Johnson, J. L., Brooks, M. B., & Sterling, T. R. (2024b). Advances in treatment strategies for rifampicin-resistant tuberculosis. The Lancet Infectious Diseases, 24(2), 101–112. https://pmc.ncbi.nlm.nih.gov/articles/PMC12248249/
Ministry of Health of the Republic of Indonesia. (2024a). Operational handbook for TB treatment RO: BPaL/BPaLM combination. Directorate of Disease Prevention and Control, Ministry of Health of the Republic of Indonesia.
Ministry of Health of the Republic of Indonesia. (2024b). National guidelines for the control of drug-resistant tuberculosis. Ministry of Health of the Republic of Indonesia.
Migliori, G. B., Tiberi, S., Zumla, A., Petersen, E., Chakaya, J. M., Wejse, C., et al. (2021). MDR/XDR-TB patient management and programmatic issues: Update 2021. International Journal of Infectious Diseases, 113(Suppl 1), S47–S54. https://doi.org/10.1016/j.ijid.2021.07.002
Pontali, E., Ambrosio, L., Sotgiu, G., et al. (2022a). BPaL regimens for drug-resistant TB: Practical aspects and implementation barriers. Respiratory Medicine, 197, 106831. https://doi.org/10.1016/j.rmed.2022.106831
Pontali, E., Sotgiu, G., Tiberi, S., Tadolini, M., Visca, D., D’Ambrosio, L., & Migliori, G. B. (2022b). Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: A systematic review. The European Respiratory Journal, 59(1), https://doi.org/10.1183/13993003.00934-2018 .
Silva, D. R., Sotgiu, G., Pontali, E., et al. (2025a). Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: A systematic review. Antibiotics, 14(1), 7. https://doi.org/10.3390/antibiotics14010007
Silva, D. R., Mello, F. C. Q., Dalcolmo, M. P., & Migliori, G. B. (2025b). Shorter regimens for drug-resistant tuberculosis: Clinical impact and public health implications. The European Respiratory Journal, 65(1), https://doi.org/10.36416/1806-3756/e20200009
Simanjuntak, A. M., Daenansya, R., Aflandhanti, P. M., Wulandari, C., & Tanjung, P. R. (2023). Efficacy of pretomanid-containing regimens for drug-resistant tuberculosis: A systematic review and meta-analysis of clinical trials. Narra Journal, 3(3), e402. https://doi.org/10.52225/narraj.v3i3.402
Sinha, A., Karim, F., Rahman, M. L., et al. (2023). The effectiveness and safety of BPaL-based regimens for rifampicin-resistant tuberculosis in non-trial settings: A prospective cohort study. Clinical Infectious Diseases. ciaf035. https://doi.org/10.1093/cid/ciaf035
World Health Organization. (2017). Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. WHO. https://www.who.int/publications/i/item/9789241550000
World Health Organization. (2022a). WHO consolidated guidelines on tuberculosis: Module 4: Treatment – Drug-resistant tuberculosis treatment. WHO. https://www.who.int/publications/i/item/9789240063129
World Health Organization. (2022b). Call to action: Shorter and more effective regimens for all people suffering from drug-resistant TB. WHO.
World Health Organization. (2022c). Rapid communication: Key changes to the treatment of drug-resistant tuberculosis. WHO.
World Health Organization. (2023a). Operational handbook on tuberculosis: Module 4: Treatment – Drug-resistant tuberculosis treatment, 2022 update. WHO. https://www.who.int/publications/i/item/9789240065116
World Health Organization. (2023b). Global tuberculosis report 2023.
World Health Organization. https://www.who.int
World Health Organization. (2023c). TB-PRACTECAL clinical trial summary. WHO. https://www.who.int/clinical-trials
World Health Organization. (2024). WHO consolidated guidelines on tuberculosis: Module 4: Treatment – Drug-resistant tuberculosis treatment. WHO.
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2026 Joy January A. S. Ninu, Nikson Eduard Faot
This work is licensed under a Creative Commons Attribution 4.0 International License.
